JDD Special Focus

Acne Case Reports

Stay up-to-date on new clinical findings on Acne. View the latest articles, case reports, editorial features, supplements, Podcast episodes and more!

 

Case Reports

Microneedling for Treatment of Acne Scars: Considerations on the Successful Management of This Aesthetic Procedure

Microneedling is a minimally invasive procedure for treating acne scars which has already been well-established, but it has been reborn in recent years because of innovative findings. It presents many advantages in comparison with other techniques more frequently used such as laser resurfacing and deep chemical peelings; in particular, it consents to achieve good or excellent results with a minimal time (2-3 days) of recovery and rare complications, even in dark phototypes.1,2 

Read Now

Sponsored

Featured Unlocked Article

Integrating Dermocosmetic Therapy for Acne: Addressing Severity Levels in Real-Life Experiences

Treating acne is not just about prescriptions—it is about pairing the right skincare routine with medical therapy. This JDD article highlights how combining pharmacological treatments with a personalized dermocosmetic regimen can improve results and keep patients on track.

Read Now

Derm Atlas

One of the key characteristics of acne is post-inflammatory hyperpigmentation and is most noticeable in darker skin tones. It is also important to point out that keloidal or hypertrophic scarring may result and should be considered when treating patients.

Here we can appreciate the erythema of inflammatory papules in lighter skin tones and the brown coloration of inflammatory papules mimicking post-inflammatory hyperpigmentation in darker skin tones.

Read Now

Podcast Episodes

State of Acne Management: Stud or Dud?

Do not pop, rather pick a therapeutic strategy from the wide array of new….oh wait, nevermind.  The world of acne treatment R&D is unfortunately shrinking as payors pick away at the medical necessity of managing the most common inflammatory skin disease. Like Marty McFly fading in that famous family photo, the spotlight on acne is shifting, enough to make Dr. Pimple Punisher Dr. Hilary Baldwin pick up a bottle of Prozac. But all hope is not lost.

Join JDD Podcast host Dr. Adam Friedman as he and Dr. Baldwin scour the therapeutic landscape and take a sharp left into the over the counter space to review accessible options to manage both the today and tomorrow of Acne Vulgaris, the symbiosis between RX and OTC to address barrier dysfunction, scarring and hyperpigmentation.

Listen Now

Sponsored

Dermatology News

AcneFeatured ArticlesLatest News
January 30, 2026

Skin Improvements in Acne Vulgaris Patients Using Gel-Matrix Moisturizer as a Complement to Topical Treatments

Barrier boost for acne care: A new gel moisturizer soothes, strengthens and lifts quality of life We’re highlighting a December 2025 article that features one of JDD’s most sought-after topics:…
Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. This article highlights Aesthetics Is Changing. Here’s What We’re Seeing?AestheticsFeatured ArticlesJDD Re:ViewLatest News
January 29, 2026

JDD Re:View With Dr. Beer

Aesthetics Is Changing. Here’s What We’re Seeing? Most dermatologists have experienced a shift in patient preferences over the past several years. There is a shift toward a minimalist, natural appearance.…
Journal of Drugs in Dermatology JDD Article about Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary SyndromeFeatured ArticlesLatest NewsSkin of Color
January 28, 2026

Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome

Trials fall short on representation - Black patients underenrolled in MF/SS studies The February issue of JDD features a review of completed US interventional trials for mycosis fungoides and Sézary syndrome…
Journal of Drugs in Dermatology JDD Article about Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab. Image shows thumb and nail or patient.Case ReportsFeatured ArticlesLatest News
January 26, 2026

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab

Case report shows dual IL‑17A/F blockade produced striking clinical and functional gains within one month in refractory ACH The February 2026 JDD issue features a case report about a 67‑year‑old…